# Partial epigenetic reprogramming Transient expression of Yamanaka reprogramming factors to reverse epigenetic markers of cellular aging without erasing cell identity — OSK gene therapy, AI-discovered reprogramming payloads and safer single-gene rejuvenation targets: Altos Labs, Retro Biosciences, NewLimit and Life Biosciences in the US, Shift Bioscience in the UK, and JingTong Life in China. Source: https://en.bioecon.ru/technology/partial-epigenetic-reprogramming/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)] Partial epigenetic reprogramming transiently expresses Yamanaka transcription factors (Oct4, Sox2, Klf4 — OSK) to reverse epigenetic markers of cellular aging, stopping before a cell loses its original identity, rather than fully reprogramming it back to a pluripotent state. Life Biosciences' lead candidate ER-100 (AAV2-OSK) is in Phase I clinical trials for optic neuropathies, described as the first-ever epigenetic restoration candidate approved for clinical trials — a world-first therapy to make cells young again given to a person — with a related OSK gene therapy also approved for glaucoma eye trials. Altos Labs, one of the best-funded longevity startups, continued advancing its partial-reprogramming rejuvenation platform through 2026, following the in vivo partial cellular reprogramming approach associated with its Belmonte-linked research. Retro Biosciences, backed by Sam Altman, closed a funding round at a $1.8 billion valuation in May 2026, working on iPSC-derived, AAV and small-molecule therapies with the help of AI models to accelerate its life-science research. NewLimit reported restoring "youthful function" to liver and immune cells through epigenetic reprogramming payload discovery, and published a January/February 2026 progress update on its AI-driven payload-discovery systems. In the UK, Shift Bioscience identified a novel single-gene target (SB000) for safer cellular rejuvenation, reversing cellular ageing as measured by DNA methylation clocks without loss of cellular identity or signs of pluripotency. In China, JingTong Life closed a tens-of-millions-yuan angel funding round for its aging-reversal research, led by CAS Star (中科创星) and Saizhi Bole, reported across multiple Chinese outlets in 2026. The key directions of partial epigenetic reprogramming are: 1. **OSK gene therapy reprogramming (OSK Gene Therapy Reprogramming):** AAV-delivered Yamanaka-factor gene therapy dosed directly in patients, the field's first clinical-stage approach — Life Biosciences' ER-100 (AAV2-OSK). 2. **Epigenetic payload discovery (Epigenetic Payload Discovery):** AI- and screening-driven discovery of reprogramming payloads that restore youthful cell function in specific tissues — NewLimit's liver and immune cell programs, Altos Labs' broader rejuvenation platform. 3. **Safer rejuvenation gene targets (Safer Rejuvenation Gene Targets):** identifying minimal, single-gene interventions that reverse epigenetic-clock aging markers without the cancer or identity-loss risk of full Yamanaka-factor reprogramming — Shift Bioscience's SB000. 4. **Cellular age-reversal platforms (Cellular Age-Reversal Platforms):** broad, well-funded platforms combining reprogramming with other longevity modalities (iPSC-derived, AAV, small-molecule therapies) — Retro Biosciences, and China's JingTong Life at an earlier funding stage. ### Sectoral value chain ``` [reprogramming factor/payload discovery] ──> [preclinical safety/efficacy validation] ──> [regulatory clearance for clinical trial (FDA/EMA/NMPA)] │ (clinical dosing/delivery) │ ▼ [indication/tissue expansion] <─── [clinical outcome data generation] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Reprogramming Factor/Payload Discovery** | identifying which transcription factors or minimal gene combinations reverse epigenetic aging markers without erasing cell identity | **In:** epigenetic-clock biomarkers, screening/AI discovery platform.
**Out:** candidate reprogramming payload. | | **Preclinical Safety/Efficacy Validation** | testing the payload in animal models for age-reversal efficacy and cancer/identity-loss risk | **In:** candidate payload, animal model.
**Out:** preclinical safety/efficacy data. | | **Regulatory Clearance for Clinical Trial** | FDA IND, EMA or NMPA clearance to begin human dosing | **In:** preclinical data package.
**Out:** cleared clinical trial. | | **Clinical Dosing/Delivery** | the reprogramming payload is delivered to patients, typically via AAV gene therapy | **In:** cleared trial protocol.
**Out:** dosed patient cohort. | | **Clinical Outcome Data** | safety, tolerability and age-reversal biomarker data are collected from dosed patients | **In:** dosed-patient cohort.
**Out:** outcome evidence. | | **Indication/Tissue Expansion** | outcome evidence supports expanding to new tissues or disease indications beyond the first clinical target | **In:** outcome evidence.
**Out:** expanded indication/tissue program. | Cross-cutting technologies of the sector: - **OSK gene therapy delivery (OSK Gene Therapy Reprogramming):** AAV vectors delivering Oct4/Sox2/Klf4 transcription factors directly to target tissue, dosed transiently to avoid full dedifferentiation. - **AI-driven payload discovery (Epigenetic Payload Discovery):** machine-learning systems screening for reprogramming payloads that restore tissue-specific youthful gene-expression patterns. - **Epigenetic clock validation (Safer Rejuvenation Gene Targets):** DNA methylation-based biomarkers (Horvath clocks) used to measure and validate cellular age reversal. --- ## US The US hosts the world's best-funded partial reprogramming companies, spanning the field's first clinical-stage gene therapy and multiple AI-driven discovery platforms. ### Life Biosciences, Altos Labs, Retro Biosciences, NewLimit, FDA - **Life Biosciences:** its lead candidate ER-100 (AAV2-OSK) is in Phase I clinical trials for optic neuropathies, described as the first-ever epigenetic restoration candidate approved for clinical trials, with a related OSK gene therapy also approved for glaucoma eye trials. - **Altos Labs:** one of the best-funded longevity startups, continued advancing its partial-reprogramming rejuvenation platform through 2026. - **Retro Biosciences:** backed by Sam Altman, closed a funding round at a $1.8 billion valuation in May 2026, working on iPSC-derived, AAV and small-molecule therapies with the help of AI models. - **NewLimit:** reported restoring "youthful function" to liver and immune cells through epigenetic reprogramming payload discovery, publishing a January/February 2026 progress update on its AI-driven discovery systems. - **FDA framework:** partial reprogramming gene therapies require FDA IND clearance to begin human dosing, with Life Biosciences' ER-100 the field's first candidate to reach that stage. --- ## CN China's confirmed partial reprogramming activity centers on an early-stage, well-connected startup that closed its first institutional funding round in 2026. ### JingTong Life, NMPA - **JingTong Life (菁童生命):** closed a tens-of-millions-yuan angel funding round for its aging-reversal research, led by CAS Star (中科创星) and Saizhi Bole, reported across multiple Chinese outlets in 2026. - **NMPA pathway:** partial reprogramming gene therapies would register with NMPA following the standard investigational gene-therapy pathway once a candidate reaches clinical readiness. --- ## EU The UK anchors Europe's partial reprogramming capacity through a company focused specifically on identifying safer, minimal-intervention rejuvenation targets rather than full Yamanaka-factor gene therapy. ### Shift Bioscience, EMA - **Shift Bioscience (UK):** identified a novel single-gene target (SB000) for safer cellular rejuvenation, reversing cellular ageing as measured by DNA methylation clocks in multiple cell types without loss of cellular identity or signs of pluripotency; the company's near-term clinical product is an antifibrotic siRNA therapeutic for cell rejuvenation, chosen for a more straightforward regulatory path to clinical proof of concept than full reprogramming. - **EMA framework:** any clinical-stage reprogramming or rejuvenation gene therapy reaching EU trials would require EMA advanced-therapy medicinal product (ATMP) clearance. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Life Biosciences** | 🇺🇸 USA | *ER-100 (AAV2-OSK)* | First epigenetic restoration candidate in clinical trials | growth | | **Altos Labs** | 🇺🇸 USA | *Partial reprogramming rejuvenation platform* | Best-funded longevity startup | research | | **Retro Biosciences** | 🇺🇸 USA | *iPSC/AAV/small-molecule therapies* | $1.8B valuation, AI-accelerated research | growth | | **NewLimit** | 🇺🇸 USA | *Epigenetic reprogramming payloads* | Liver/immune cell rejuvenation | growth | | **Shift Bioscience** | 🇬🇧 UK | *SB000 single-gene target* | Safer rejuvenation, no pluripotency signs | growth | | **JingTong Life** | 🇨🇳 China | *Aging-reversal research platform* | Angel-funded 2026 | growth | --- ## Tech stack and innovations The stack applies transient transcription-factor expression or targeted single-gene intervention to reverse epigenetic aging markers while preserving a cell's original functional identity. 1. **OSK gene therapy reprogramming (OSK Gene Therapy Reprogramming):** - Life Biosciences' ER-100 delivers AAV2-OSK directly to patients, the field's first candidate to reach human dosing, targeting optic neuropathies and glaucoma-related vision loss. 2. **Epigenetic payload discovery (Epigenetic Payload Discovery):** - NewLimit's AI-driven discovery systems identify reprogramming payloads that restore youthful gene-expression patterns in liver and immune cells, while Altos Labs pursues a broader rejuvenation platform. 3. **Safer rejuvenation gene targets (Safer Rejuvenation Gene Targets):** - Shift Bioscience's SB000 single-gene target reverses DNA methylation-clock aging markers without the cancer or identity-loss risk associated with full Yamanaka-factor reprogramming. 4. **Broad cellular age-reversal platforms (Cellular Age-Reversal Platforms):** - Retro Biosciences combines iPSC-derived, AAV and small-molecule modalities with AI-accelerated research, while JingTong Life represents an earlier-stage entrant pursuing the same broad aging-reversal thesis in China. --- ## Value chains and production pipelines ### Industrial pipeline of a partial reprogramming therapy (FDA IND / EMA ATMP / NMPA) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Reprogramming factor/ │ ───> │ 2. Preclinical safety/ │ │ payload discovery │ │ efficacy validation │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Clinical dosing/ │ <─── │ 3. Regulatory clearance │ │ delivery │ │ for clinical trial │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Clinical outcome data │ ───> │ 6. Indication/tissue │ │ │ │ expansion │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Reprogramming factor and payload discovery Which transcription factors or minimal gene combinations reverse epigenetic aging markers without erasing cell identity are identified, as with Shift Bioscience's discovery of its single-gene SB000 target versus the full OSK approach used by Life Biosciences. #### Stage 2: Preclinical safety and efficacy validation The payload is tested in animal models for age-reversal efficacy and cancer/identity-loss risk, the validation step behind Shift Bioscience's demonstration that SB000 reverses methylation-clock aging without pluripotency signs. #### Stage 3: Regulatory clearance for clinical trial FDA IND, EMA or NMPA clearance is obtained to begin human dosing, with Life Biosciences' ER-100 the field's first candidate to reach this stage for optic neuropathies. #### Stage 4: Clinical dosing and delivery The reprogramming payload is delivered to patients, typically via AAV gene therapy, as with Life Biosciences' AAV2-OSK dosing described as the first time cells have been rejuvenated in a living person. #### Stage 5: Clinical outcome data generation Safety, tolerability and age-reversal biomarker data are collected, the evidence base Life Biosciences is generating in its Phase I optic-neuropathy and glaucoma trials. #### Stage 6: Indication and tissue expansion Outcome evidence supports expanding to new tissues or disease indications, the pattern behind NewLimit's parallel liver and immune-cell programs and the broader multi-modality platforms Altos Labs and Retro Biosciences are building around their initial reprogramming research.